Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
        • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
      • Recently Published Guidelines
    • Bridging Disciplines
    • → Articles Bridging Discplines
    • Go Red for Women Issue
    • Cardiovascular Case Series
    • Circulation at ESC
    • Circulation at AHA Scientific Sessions
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation at ACC 2018
    • Circulation Supplements
    • ECG Challenge
    • Hospitals of History
      • Brigham and Women's Hospital
      • Hartford Hospital
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Instituto do Coração-INCOR (São Paulo, Brasil)
      • Minneapolis City Hospital
      • Parkland Hospital: Dallas, Texas
      • Pennsylvania Hospital, Philadelphia
      • Pitié-Salpêtrière Hospital
      • Royal Infirmary of Edinburgh, Scotland
      • Tufts Medical Center
      • University of Michigan
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
      • Women's College Hospital, Toronto, Canada
      • Henry Ford Hospital, Detroit, Michigan
      • Instituto Nacional de Cardiología Ignacio Chávez – INCICh México City, México
      • Kuang-Tien General Hospital (Taichug, Taiwan)
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • → Articles Bridging Discplines
    • Go Red for Women Issue
    • Cardiovascular Case Series
    • Circulation at ESC
    • Circulation at AHA Scientific Sessions
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation at ACC 2018
    • Circulation Supplements
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Endocarditis in Congenital Heart Disease

Who Is at Highest Risk?

Barbara J.M. Mulder
Download PDF
https://doi.org/10.1161/CIRCULATIONAHA.113.005220
Circulation. 2013;128:1396-1397
Originally published September 23, 2013
Barbara J.M. Mulder
From the Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
Loading
  • Editorials
  • endocarditis
  • heart diseases

The risk of infective endocarditis (IE) remains a major concern in patients with congenital heart disease (CHD), whether unrepaired, palliated, or corrected. The overall incidence of endocarditis in adults with CHD has been reported to be 11 per 100 000 person-years, which is a considerable increase compared with the general population, in which a rate of 1.5 to 6.0 per 100 000 patient-years has been reported.1,2 In children, the incidence of IE in the general population is ≈3 times lower.3

Article see p 1412

CHD is the most prevalent underlying cardiac condition in patients with IE. Despite recommendations for antibiotic prophylaxis of IE, increased survival of children with CHD and the use of conduits and prostheses in corrective surgery may have contributed to an increasing incidence of IE.4 However, CHD-associated IE mortality has decreased substantially to 10% because of improvements in the diagnosis of IE, antimicrobial treatment, cardiac surgery, and interventional therapy.3,5 Given the prognosis, morbidity, and high cost of management of IE, IE prophylaxis has long been recommended in an attempt to minimize the incidence of IE.

However, no randomized study has been conducted yet to elucidate the efficacy and usefulness of IE prophylaxis. Based on case-control studies, expert opinions, and daily practice, guidelines on IE prophylaxis from international cardiology societies in 2008/2009 were greatly simplified and resulted in a drastic reduction in and limitation of cardiac diseases and procedures in which IE prophylaxis is indicated.6,7 The guidelines now emphasize the role of primary prevention and limit antibiotic prophylaxis to the highest-risk patients undergoing the highest-risk procedures. Motivated largely by lack of robust evidence of the effectiveness of antibiotic prophylaxis and a growing recognition of the importance of bacteremias from routine daily activities in causing IE, antibiotic prophylaxis was deemed reasonable in only a select group of high-risk patients. However, changes in the preexisting guidelines were based on limited data. Owing to a lack of evidence, all recent recommendations are Class IIa and Level of Evidence B or C, similar to the level of evidence of the previous recommendations.

At this time, surveillance with administrative databases and more detailed record review may be useful in ascertaining whether the adoption of the revised IE prophylaxis guidelines has changed the prevalence of IE. In addition, for improvement in future IE prevention guidelines, further studies are needed to gain insight into cardiac lesions and procedures at highest risk of developing IE.

Against this background, Rushani et al8 provide important new information. Using a population-based analysis, the authors report the cumulative incidence and predictors of IE in children (0–18 years of age) with CHD using the Quebec CHD Database from 1988 to 2010. Of 34 279 children who were followed up since birth and contributed 328 185 person-years up to 18 years of age, 136 cases of IE were observed. The cumulative incidence of IE from birth to 18 years of age in all CHD lesions combined was 6.1 first cases per 1000 children, corresponding to an incidence rate of 4.1 per 10 000 person-years. Analysis of the predictors of IE involved a comparison of 185 patients with IE and their 3700 calendar time–matched controls from the full population of 47 518 children with CHD. Cyanotic CHD lesions, left-sided lesions, and endocardial cushion defects were associated with an increased risk of IE acquisition in childhood. The relative risk of developing IE was substantially elevated during the 6-month postoperative period of cardiac surgery and in children <3 years of age.

The data are unique in this population-based approach but are limited by the validity and scope of the data used. Although the data sources ensured province-wide inclusion of children with CHD in the cohort, they are prone to misclassification error and lack clinical information, which can limit the validity and generalizability of the data.

How can these data improve our insight into cardiac lesions and procedures at highest risk of developing IE? How will the presented results of this Quebec study be relevant for future revision of guidelines? The population-based approach and the large number of patients allowed an estimation of the cumulative incidence of IE in children with CHD. The overall rate of IE was ≈3 times lower than the published estimate in adults with CHD.1 The reduced frequency of IE in children compared with adults with CHD parallels the trend in the general population. In future revisions of guidelines, these data on the incidence of IE in children with CHD may be important.

In line with the current guidelines for antibiotic prophylaxis, cyanotic CHD lesions and cardiac surgery in the previous 6 months were found to be strongly associated with the development of IE. The risk of IE, however, was also elevated among patients with left-sided lesions and endocardial cushion defects, even in children with no previous valve surgery or history of IE, 2 conditions currently included in the high-risk category for IE. Should patients with left-sided lesions and endocardial cushion defects therefore be considered eligible for IE prophylaxis in future revisions of IE guidelines? The results should be interpreted with caution because a lack of clinical information, inherent to the study design, makes accurate risk assessment somewhat delicate in several aspects. Importantly, as expected, the risk of IE varied markedly across the CHD lesions in the study by Rushani et al.8 However, the infrequency of IE prevented investigation of CHD lesions individually. CHD lesions were grouped into categories of comparable IE risk, but not all constituent lesions of the group shared identical IE susceptibility. Although, for example, 3 important subgroups of left-sided lesions—aortic coarctation, aortic valve disease, and mitral valve disease—showed a comparable IE risk, this finer breakdown led to fewer IE events per lesion and prohibited any statistical analysis. Because in most studies the incidence of IE has been reported to be substantially higher for aortic valve stenosis than for aortic coarctation,9,10 left-sided lesions as an overall group should not be considered eligible for IE prophylaxis in future guideline revisions. A further refining of the data is needed for an accurate estimation of patients at highest risk of IE. Similarly, within the cyanotic CHD group, the data did not permit a distinction between cyanosis in infancy (associated with the native anatomy) and chronic cyanosis. Moreover, the impact of spontaneous closures of ventricular septal defects could not be assessed, which might explain the remarkably low incidence of IE in ventricular septal defect patients. Ventricular septal defect is usually considered a high-risk defect in both children and adults.9,11 On the other hand, it has been suggested that IE is related primarily to associated valve disease rather to the septal defect itself.12

These limitations are obviously inherent to such a large population-based study. The present findings have to be extended with more clinical studies in which more subtle clinical data are available to discriminate the risk of IE between cardiac defects within combined subgroups.

Sex has been recognized to be an important risk factor for IE in adults. Men are affected at least twice as often as women. In children, the male-to-female ratio seems lower at 1.2:1,9 and in the Quebec study, a comparable IE frequency in males and females was observed. It is possible that high-risk behaviors and other lifestyle factors may be less likely to differ between males and females during childhood.

In summary, it has to be emphasized that our insight in CHD patients at high risk for IE is still limited. The question of who is at highest risk for the development of endocarditis within the CHD population remains largely unanswered. Still, the authors of the present study have taken a significant step to fill the gap of knowledge. The population-based cohort study design importantly allowed assessment of overall IE incidence in children with CHD. The authors compared combined groups of cardiac defects and estimated both relative and absolute risks in this population. This approach may form the basis for further studies comparing individual lesions within combined patient groups. Whether the use of antibiotic prophylaxis should be extended to patient groups and procedures not included in the current recommendations requires further research. These studies are required for future revision of IE prevention guidelines. Other crucial studies should include an evaluation of the protective efficacy and cost-effectiveness of prophylaxis and an evaluation of the relative importance of bacteremias from routine daily activities versus invasive procedures in causing IE. On the basis of studies such as that reported by the Quebec investigators, a future revision of IE prevention guidelines might lead to future recommendations that are based on much more robust data and substantial evidence.

Disclosures

None.

Footnotes

  • The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

  • © 2013 American Heart Association, Inc.

References

  1. 1.↵
    1. Verheugt CL,
    2. Uiterwaal CS,
    3. van der Velde ET,
    4. Meijboom FJ,
    5. Pieper PG,
    6. Veen G,
    7. Stappers JL,
    8. Grobbee DE,
    9. Mulder BJ
    . Turning 18 with congenital heart disease: prediction of infective endocarditis based on a large population. Eur Heart J. 2011;32:1926–1934.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Mylonakis E,
    2. Calderwood SB
    . Infective endocarditis in adults. N Engl J Med. 2001;345:1318–1330.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Coward K,
    2. Tucker N,
    3. Darville T
    . Infective endocarditis in Arkansan children from 1990 through 2002. Pediatr Infect Dis J. 2003;22:1048–1052.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Day MD,
    2. Gauvreau K,
    3. Shulman S,
    4. Newburger JW
    . Characteristics of children hospitalized with infective endocarditis. Circulation. 2009;119:865–870.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Sadiq M,
    2. Nazir M,
    3. Sheikh SA
    . Infective endocarditis in children–incidence, pattern, diagnosis and management in a developing country. Int J Cardiol. 2001;78:175–182.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Nishimura RA,
    2. Carabello BA,
    3. Faxon DP,
    4. Freed MD,
    5. Lytle BW,
    6. O’Gara PT,
    7. O’Rourke RA,
    8. Shah PM,
    9. Bonow RO,
    10. Carabello BA,
    11. Chatterjee K,
    12. de Leon AC Jr.,
    13. Faxon DP,
    14. Freed MD,
    15. Gaasch WH,
    16. Lytle BW,
    17. Nishimura RA,
    18. O’Gara PT,
    19. O’Rourke RA,
    20. Otto CM,
    21. Shah PM,
    22. Shanewise JS,
    23. Smith SC Jr.,
    24. Jacobs AK,
    25. Buller CE,
    26. Creager MA,
    27. Ettinger SM,
    28. Krumholz HM,
    29. Kushner FG,
    30. Lytle BW,
    31. Nishimura RA,
    32. Page RL,
    33. Tarkington LG,
    34. Yancy CW Jr.
    ; American College of Cardiology/American Heart Association Task Force. ACC/AHA guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;118:887–896.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Habib G,
    2. Hoen B,
    3. Tornos P,
    4. Thuny F,
    5. Prendergast B,
    6. Vilacosta I,
    7. Moreillon P,
    8. de Jesus Antunes M,
    9. Thilen U,
    10. Lekakis J,
    11. Lengyel M,
    12. Müller L,
    13. Naber CK,
    14. Nihoyannopoulos P,
    15. Moritz A,
    16. Zamorano JL
    ; ESC Committee for Practice Guidelines. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2009;30:2369–2413.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Rushani D,
    2. Kaufman JS,
    3. Ionescu-Ittu R,
    4. Mackie AS,
    5. Pilote L,
    6. Therrien J,
    7. Marelli AJ
    . Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors. Circulation. 2013;128:1412–1419.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Knirsch W,
    2. Nadal D
    . Infective endocarditis in congenital heart disease. Eur J Pediatr. 2011;170:1111–1127.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Di Filippo S
    . Prophylaxis of infective endocarditis in patients with congenital heart disease in the context of recent modified guidelines. Arch Cardiovasc Dis. 2012;105:454–460.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Fortún J,
    2. Centella T,
    3. Martín-Dávila P,
    4. Lamas MJ,
    5. Pérez-Caballero C,
    6. Fernández-Pineda L,
    7. Otheo E,
    8. Cobo J,
    9. Navas E,
    10. Pintado V,
    11. Loza E,
    12. Moreno S
    . Infective endocarditis in congenital heart disease: a frequent community-acquired complication. Infection. 2013;41:167–174.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Gabriel HM,
    2. Heger M,
    3. Innerhofer P,
    4. Zehetgruber M,
    5. Mundigler G,
    6. Wimmer M,
    7. Maurer G,
    8. Baumgartner H
    . Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. J Am Coll Cardiol. 2002;39:1066–1071.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation
September 24, 2013, Volume 128, Issue 13
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Endocarditis in Congenital Heart Disease
    Barbara J.M. Mulder
    Circulation. 2013;128:1396-1397, originally published September 23, 2013
    https://doi.org/10.1161/CIRCULATIONAHA.113.005220

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Endocarditis in Congenital Heart Disease
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    Endocarditis in Congenital Heart Disease
    Barbara J.M. Mulder
    Circulation. 2013;128:1396-1397, originally published September 23, 2013
    https://doi.org/10.1161/CIRCULATIONAHA.113.005220
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Heart Failure and Cardiac Disease
    • Congenital Heart Disease

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured